Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Renal Cell 23Kidney Neoplasms 10Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Carcinoma 6Melanoma 4Lung Neoplasms 4Colorectal Neoplasms 4Neoplasm Metastasis 3Carcinoma, Hepatocellular 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Kidney Diseases 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Adenoid Cystic 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1

Interventions

Platinum 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Cisplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2rocakinogene sifuplasmid 1fludarabine phosphate 1fludarabine 1durvalumab 1alovudine 1aldesleukin 1Vaccines, Synthetic 1VGX-3100 1Sonazoid 1Respiratory Function Tests 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Imaging 1MEDI0457 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Vulvar Neoplasms × Axitinib × Clear all
NCT05949632 2026-06-04

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Incyte Corporation

Phase 1/2 Terminated
5 enrolled 13 charts
GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡